RecruitingNot applicableNCT07126678

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

Studying Follicular lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The First Affiliated Hospital with Nanjing Medical University
Intervention
zanubrutinib, bendamustine, and obinutuzumab(drug)
Enrollment
15 target
Eligibility
18-75 years · All sexes
Timeline
2025 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07126678 on ClinicalTrials.gov

Other trials for Follicular lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Follicular lymphoma →

← Back to all trials